Novo Nordisk stock plummeted Tuesday after the drugmaker reported lighter-than-expected June-quarter sales for its new obesity-fighting pill, intensifying a high-stakes market battle with rival Eli Lilly. According to Investor’s Business Daily, the company’s Wegovy pill generated about $496 million during the second quarter, missing analyst forecasts of $509 million and sending shares down more than 6% to 44.07 in midday trades.
Novo Nordisk Battles Eli Lilly in the Weight-Loss Pill Market
The intensifying race for oral weight-loss treatments has put heavy pressure on both pharmaceutical giants. According to FactSet data cited by Investor’s Business Daily, Lilly is scheduled to report second-quarter earnings early Wednesday, with analysts expecting $103 million in sales for its competing pill, Foundayo.
Pro Tip: When evaluating pharmaceutical growth stocks, closely monitor quarterly prescription starts alongside top-line revenue to gauge true market adoption before supply constraints ease.
Manufacturing Constraints and Supply Scale Challenges
Growth for Novo Nordisk hinges largely on the surging demand for GLP-1-based weight-loss drugs. The company’s new pill has already reached more than 5 million prescriptions, maintaining its position as the leader in new patient starts. Zacks Investment Management Chief Market Strategist Brian Mulberry noted in an email to Investor’s Business Daily that consumer preference for oral options could unlock 30% to 40% growth into the next year.
“That all comes down to execution, though, and Novo has (seen) headwinds in ramping up scale to compete with their larger peers,” Mulberry said in his email to Investor’s Business Daily. He added that while some manufacturing constraints have eased, scale remains essential for Novo Nordisk to effectively compete with Eli Lilly.
Injections and Diabetes Treatments Offset Pill Shortfalls
Despite the stumble in oral weight-loss sales, other segments of Novo Nordisk’s portfolio delivered mixed results. Revenue from injectable Wegovy rose 1% to roughly $3 billion, slightly beating FactSet analyst calls for $2.91 billion. Meanwhile, the type 2 diabetes treatment Ozempic—which shares the same semaglutide chemical backbone—brought in $4.84 billion, growing 3% and easily surpassing Wall Street projections of $4.07 billion.
Rybelsus, the pill form of Ozempic, generated about $806 million in sales. Though down 7% year over year, that figure still topped analyst forecasts of $703 million. Looking ahead, Novo Nordisk expects full-year sales and adjusted operating profit to be flat to down 6% year over year, marking an improvement over its guidance from three months prior, which projected a 4% to 12% drop.
Did you know? Ozempic and the oral pill Rybelsus both rely on the exact same semaglutide chemical backbone, serving millions of patients globally for type 2 diabetes management.
Frequently Asked Questions
Why did Novo Nordisk stock drop?
Novo Nordisk stock dropped more than 6% after reporting second-quarter sales for its new obesity pill that fell short of Wall Street forecasts.
How much did Wegovy pill sales generate in the second quarter?
According to Investor’s Business Daily, the Wegovy pill generated about $496 million in sales during the second quarter, missing expectations of $509 million.
What is Eli Lilly’s competing weight-loss pill?
Eli Lilly’s competing weight-loss pill is called Foundayo, which analysts expected to report $103 million in second-quarter sales.
To stay updated on the latest developments in growth stocks and pharmaceutical earnings, explore our latest stock market insights or subscribe to our newsletter for daily updates.
Related reading